LONDON, Nov 23 (Reuters) - AstraZeneca will have 200 million
doses of its candidate vaccine developed by the University of
Oxford by the end of 2020, with 700 million doses ready globally
by the end of the first quarter of 2021, operations executive
Pam Cheng said on Monday.
Cheng told a briefing that there would be 20 million doses
in Britain by the end of the year, with 70 million doses for the
UK by the end of Q1 2021.
(Reporting by Guy Faulconbridge and Kate Holton, writing by
Alistair Smout, Editing by Catherine Evans)